News
10th February 2020

Join us at Cancer Progress May 5-6, NYC

Join us at Cancer Progress May 5-6, NYC

Join us for 2 days of insightful discussion, vigorous debate and generous networking at the 31st annual Cancer Progress Conference May 5-6 in NYC. Guests include eminent Keynote Speaker Michael A. Curran, PhD (Associate Professor, Dept. of Immunology Scientific Director ORBIT Platform, The University of Texas MD Anderson Cancer Center, Department of Immunology, Division of Basic Sciences)

#CancerProgressNYC20

Cancer Progress Panels

  • Paradigm-shifting platforms I, IO: Taking IO to the next Level
  • Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable
  • Investing into Oncology: Who, What and Where?
  • Vaccines: From Paleo to Neo, Cancer Vaccines in the New Age of IO
  • Next Wave of Diagnostics, Including Precision IO: Early and Smarter, the Better to Cure
  • Inflecting Value in Early Stage Biotech ( in an Increasingly Cost Conscious Environment): Linking Proof of Relevance to Pricing & Reimbursement

Advanced Therapeutics

  • Antigen/platform pairings (“Forget Wine and Cheese…Get this Right and Your Valuation Takes Flight”)
  • State of the union for off-the-shelf (“In an ‘Allo or Bust’ Market, What’s Rising to the Top of the Shelf?”)
  • What are investors and partners looking for today (“How to Stand Out/Inflect Value in a Frothy Vat of Cells”)

Related Articles

Arsenal Capital Partners Completes £182 million Acquisition of Cello Health
11 August 2020
Arsenal Capital Partners Completes £182 million Acquisition of Cello Health

The acquisition of Cello Health provides the foundation for a new enterprise to enable healthcare and biopharmaceutical clients to maximize the value of their products.

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us